Journal Options HIV
Course Directors: Joseph J. Eron, Jr., MD, Andrew R. Zolopa, MD, William G. Powderly, MD
Recent Articles
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F, Lapidus N, Bedossa P, et al.
Clin Infectious Dis. 2008;46:768-774.
Capsule Summary Expert Commentary Abstract Slides
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF, Flandre P, Delaugerre C, et al.
AIDS. 2008;22:385-393.
Capsule Summary Expert Commentary Abstract Slides
Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men.
Ghosn J, Thibault V, Delaugerre C, et al.
AIDS. 2008;22:658-661.
Capsule Summary Expert Commentary Abstract Slides
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, et al.
J Acquir Immune Defic Syndr. 2008;47:212-220.
Capsule Summary Expert Commentary Abstract Slides
Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.
Kalayjian RC, Franceschini N, Gupta SK, et al.
AIDS. 2008;22:481-487.
Capsule Summary Expert Commentary Abstract Slides
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.
Long JL, Engels EA, Moore RD, Gebo KA.
AIDS. 2008;22:489-496.
Capsule Summary Expert Commentary Abstract Slides
HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S, Phillips E, Carosi G, et al.
N Engl J Med. 2008;358:568-579.
Capsule Summary Expert Commentary Abstract Slides
Immunologic, Virologic, and Clinical Consequences of Episodes of Transient Viremia During Suppressive Combination Antiretroviral Therapy.
van Sighem A, Zhang S, Reiss P, et al.
J Acquir Immune Defic Syndr. 2008;48:104-108.
Capsule Summary Expert Commentary Abstract Slides
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy.
Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr. 2007;46:607-615.
Capsule Summary Expert Commentary Abstract Slides
Factors associated with the selection of mutations conferring resistance to protease inhibitors in PI experienced patients displaying treatment failure on Darunavir.
Lambert-Niclot S, Flandre P, Canestri A, et al.
Antimicrob Agents Chemother. 2008;52:491-496.
Capsule Summary Expert Commentary Abstract Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|